Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary

Abstract

FDG-PET/CT imaging is very helpful in the search for the presence of a malignancy in patients with carcinoma of unknown primary syndrome. FDG-PET/CT is less accurate in identifying exactly the site of a primary. Discovery of a hypermetabolic lesion was associated with the worst survival rate.

Lymph Node Metastasis of Squamous Cell Carcinoma from an Unknown Primary in the Upper and Middle Neck: Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography

“…To date, only one study, by Fencl et al, suggested that FDG-PET/CT in CUP patients might indeed affect outcome. 31 In this series, the survival rate of CUP patients with at least one hypermetabolic lesion proved significantly lower when compared with the remaining CUP patients. Additional studies addressing this issue are warranted.…”

18F-FDG PET/CT as a Diagnostic Tool in Patients with Extracervical Carcinoma of Unknown Primary Site: A Literature Review

“…By using a set of defined search and selection criteria we identified eight studies in the PubMed database evaluating 18 F-FDG PET/CT in this patient population. Furthermore, analysis of these studies revealed that relevant data could be extracted from only four of these publications [13][14][15][16]. Of these four studies, only the study by Gutzeit et al [18] used a diagnostic CT scan with a standard radiation dose (130 mAs) and i.v.…”

“…Four articles/studies were excluded for the following reasons: (a) duplicate study [13], (b) data on CUP patients with extracervical metastases were not extractable [14,15], and (c) part of the study population underwent 18 F-FDG PET alone and was not analyzed separately from patients undergoing 18 F-FDG PET/CT [16].…”

Diagnostic management of inaugural bone metastases

“…Cette technique qui dé tecte des processus hypermé taboliques a l'avantage d'une ré solution spatiale é levé e (aux alentours de 5 mm) et de permettre l'exploration du corps entier en un seul examen. Son utilisation, en cas de mé tastase d'origine indé -terminé e, paraît logique et pourrait thé oriquement guider toute investigation complé mentaire [2,9,11,26]. Toutefois, la sensibilité est variable d'un type tumoral à l'autre, moindre dans les cancers prostatiques, ré naux et hé patocarcinomes et globalement dans les tumeurs faiblement prolifé ratives [12,27].…”